title: [Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].
abstract: BACKGROUND
  Bevacizumab is recommended in first line chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC). Paclitaxel is a doublet drug also widely used in cisplatin-based regimens. Paclitaxel plus bevacizumab is a standard regimen as first line treatment of metastatic breast cancer. Since there is no guideline for third line treatment of NSCLC, some oncology units use paclitaxel-bevacizumab in some NSCLC patient after relapse of the second line. The aim of this study was to assess retrospectively the feasibility and efficacy of this treatment option in stage IV NSCLC.
  
  
  METHODS
  Patients who had received the combination of paclitaxel (80 to 90 mg/m(2) in a weekly schedule) and bevacizumab (7.5 to 15 mg/kg every 21 days) in the thoracic oncology departments of two university hospitals in the Rhone-Alpes Department were retrospectively reviewed.
  
  
  RESULTS
  Twelve patients underwent this treatment. Their mean age was 56 years and their performance status was less or equal to 1 in 50 % of the cases. The chemotherapy was given as fifth line in 67 % of the patients and 67 % were antiangiogenic naïve. They received a mean of 6 courses. The overall response rate was 33 % and the disease control rate 66 %. Median progression-free survival was 5.1 months (95 %CI 1.0-9.1). Ten patients (82 %) experienced toxicity, the majority grade 1 to 2 events, and only one a grade 3 event (febrile neutropenia). There were no severe bleeding episodes.
  
  
  CONCLUSIONS
  Combined paclitaxel-bevacizumab chemotherapy seems feasible in patients with NSCLC. The toxicity profile is acceptable. This regimen should be evaluated in further prospective studies.
authors.affiliation: Service de pneumologie et oncologie thoracique, hospices civils de Lyon, CH Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Faculté de médecine et de maïeutique Lyon-Sud - Charles-Mérieux, université Lyon-1, 69600 Oullins, France.
authors.forename: V
authors.initials: V
authors.lastname: Zarza
authors.affiliation: Service de pneumologie et oncologie thoracique, hospices civils de Lyon, CH Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Faculté de médecine et de maïeutique Lyon-Sud - Charles-Mérieux, université Lyon-1, 69600 Oullins, France. Electronic address: sebastien.couraud@chu-lyon.fr.
authors.forename: S
authors.initials: S
authors.lastname: Couraud
authors.affiliation: Service de pneumologie et oncologie thoracique, CHU Michallon, 38700 La Tronche, France; Institut Albert-Bonniot, U823, université Joseph-Fourier, 38042 Grenoble cedex 9, France.
authors.forename: C
authors.initials: C
authors.lastname: Bosc
authors.affiliation: Service de pneumologie et oncologie thoracique, CHU Michallon, 38700 La Tronche, France; Institut Albert-Bonniot, U823, université Joseph-Fourier, 38042 Grenoble cedex 9, France.
authors.forename: A-C
authors.initials: AC
authors.lastname: Toffart
authors.affiliation: Service de pneumologie et oncologie thoracique, CHU Michallon, 38700 La Tronche, France; Institut Albert-Bonniot, U823, université Joseph-Fourier, 38042 Grenoble cedex 9, France.
authors.forename: D
authors.initials: D
authors.lastname: Moro-Sibilot
authors.affiliation: Service de pneumologie et oncologie thoracique, hospices civils de Lyon, CH Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Faculté de médecine et de maïeutique Lyon-Sud - Charles-Mérieux, université Lyon-1, 69600 Oullins, France.
authors.forename: P-J
authors.initials: PJ
authors.lastname: Souquet
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000032:analysis; D061067:Antibodies, Monoclonal, Humanized / Q000032:analysis; D000972:Antineoplastic Agents, Phytogenic / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000032:analysis; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D017239:Paclitaxel
keywords: Bevacizumab; Cancer bronchique non à petites cellules; Chemotherapy; Chimiothérapie; Metastatic stage; Non-small cell lung cancer; Paclitaxel; Stade métastatique